“The acceptance of the Epioxa NDA represents another important step in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal ...

Needham raised the firm’s price target on Glaukos (GKOS) to $176 from $149 and keeps a Buy rating on the shares after its Q4 results. The company’s iDose revenue grew sequentially to $16M and ...